Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Arvinas, Inc. - Common Stock (NQ:ARVN)

9.310 -0.350 (-3.62%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Arvinas, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Why Seagate Shares Are Trading Lower By More Than 7%? Here Are 49 Stocks Moving In Wednesday's Mid-Day Session
Gainers ESSA Pharma Inc. (NASDAQ: EPIX) shares surged 59.3% to $2.7417 after the company highlighted updates results from the Phase 1/2 study of EPI-7386 with Enzalutamide At the 29th Annual Prostate... 
Via Benzinga
Wingstop, Harley-Davidson, Rollins And Some Other Big Stocks Moving Higher On Wednesday
U.S. stocks traded mixed, with the Dow Jones gaining more than 200 points on Wednesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Where Arvinas Stands With Analysts
Within the last quarter, Arvinas (NASDAQ:ARVN) has observed the following analyst ratings: 
Via Benzinga
Expert Ratings for Arvinas
Within the last quarter, Arvinas (NASDAQ:ARVN) has observed the following analyst ratings: 
Via Benzinga
Recap: Arvinas Q2 Earnings
  Arvinas (NASDAQ:ARVN) reported its Q2 earnings results on Thursday, August 4, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Arvinas Appoints Paul McInulty as Senior Vice President, Regulatory Affairs
From Arvinas Inc.
Via GlobeNewswire
Arvinas Gives Back to Local Greater New Haven Community
From Arvinas Inc.
Via GlobeNewswire
Arvinas's Return on Invested Capital Insights
According to Benzinga Pro data, Arvinas (NASDAQ:ARVN) reported Q2 sales of $31.30 million. Earnings fell to a loss of $70.00 million, resulting in a 10.41% decrease from last quarter. 
Via Benzinga
Sanofi's Breast Cancer Drug Fallout 'Creates Buying Opportunity' For This Stock
According to Oppenheimer analyst, the fallout of Sanofi SA's (NASDAQ: SNY) amcenestrant creates a buying opportunity for Arvinas Inc (NASDAQ: ARVN)  
Via Benzinga
7 Analysts Have This to Say About Arvinas
Arvinas (NASDAQ:ARVN) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Analyst Ratings for Arvinas
Arvinas (NASDAQ:ARVN) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Arvinas: Q1 Earnings Insights
Arvinas (NASDAQ:ARVN) reported its Q1 earnings results on Thursday, May 5, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2022
Upgrades 
Via Benzinga
Sanofi, Children's Place And Some Other Big Stocks Moving Lower On Wednesday
  Embark Technology, Inc. (NASDAQ: EMBK) fell 25.1% to $12.40. Embark Technology reported the completion of reverse stock split. 
Via Benzinga
Expert Ratings For Arvinas
Arvinas (NASDAQ:ARVN) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Arvinas: Q4 Earnings Insights
Arvinas (NASDAQ:ARVN) reported its Q4 earnings results on Monday, February 28, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Earnings... 
Via Benzinga
This Healthcare Stock Dipped Over 30%; Here Are 83 Biggest Movers From Yesterday
Gainers 
Via Benzinga
Why Blue Water Vaccines Is Trading Higher By Around 80%, Here Are 61 Stocks Moving In Wednesday's Mid-Day Session
Gainers Blue Water Vaccines, Inc. (NASDAQ: BWV) shares jumped 79.5% to $4.57 after the company announced it plans to explore the potential development of a novel monkeypox vaccine using its norovirus... 
Via Benzinga
8 Analysts Have This to Say About Arvinas
  Over the past 3 months, 8 analysts have published their opinion on Arvinas (NASDAQ:ARVN) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a... 
Via Benzinga
Do You Have Biotech FOMO? It Might Be Time To Pay Attention To These Names
Biotech stocks continued going gangbusters Wednesday. Here's why, experts say. 
Via Investor's Business Daily
Do You Have Biotech FOMO? Why Cogent, Arvinas And Others Are Flying
Biotech stocks continued going gangbusters Wednesday. Here's why, experts say. 
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For June 21, 2022
Upgrades 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 9, 2022
Upgrades 
Via Benzinga
What 6 Analyst Ratings Have To Say About Arvinas
Over the past 3 months, 6 analysts have published their opinion on Arvinas (NASDAQ:ARVN) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 28, 2022
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 6, 2022
Upgrades 
Via Benzinga
Arvinas Earnings Perspective: Return On Capital Employed
Benzinga Pro data, Arvinas (NASDAQ:ARVN) reported Q4 sales of $26.30 million. Earnings fell to a loss of $53.00 million, resulting in a 13.35% decrease from last quarter. In Q3,... 
Via Benzinga
Where Arvinas Stands With Analysts
Arvinas (NASDAQ:ARVN) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 2... 
Via Benzinga
3 Stocks To Double Down On In 2022
The markets are entering somewhat uncertain territory, as the S&P 500 recently experienced its 39th correction since the beginning of 1950 due to a combination... 
Via Benzinga
Arvinas Highlights New ARV-110 Data In Prostate Cancer Patients
Arvinas Inc (NASDAQ: ARVN) announced the presentation of new data from completed Phase 1 dose-escalation and ongoing Phase 2 ARDENT expansion cohort with... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.